Gold Myelinated Axon_edited_edited_edite

Decoding Neurological Disease. Building Medicines.

CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a more translationally informed approach to drug discovery.

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Partner With Us
We welcome strategic collaborations with pharmaceutical companies, research institutions, and investors who share our commitment to advancing CMT1A therapeutics and the PRECISION™ platform.

Interested in our CMT1A program?

MEET US AT

A New Model for Neurotherapeutics We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Interested in our CMT1A program? MEET US AT

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Interested in our CMT1A program?

MEET US AT